Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry.

clear-cell ovarian carcinoma early-stage ovarian carcinoma endometrioid ovarian carcinoma histotype-specific prognostic biomarkers immunohistochemistry mucinous ovarian carcinoma

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 09 12 2019
accepted: 29 01 2020
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 7 3 2020
Statut: epublish

Résumé

Early-stage (I and II) ovarian carcinoma patients generally have good prognosis. Yet, some patients die earlier than expected. Thus, it is important to stratify early-stage patients into risk groups to identify those in need of more aggressive treatment regimens. The prognostic value of 29 histotype-specific biomarkers identified using RNA sequencing was evaluated for early-stage clear-cell (CCC), endometrioid (EC) and mucinous (MC) ovarian carcinomas (

Identifiants

pubmed: 32133296
doi: 10.3389/fonc.2020.00162
pmc: PMC7040170
doi:

Types de publication

Journal Article

Langues

eng

Pagination

162

Informations de copyright

Copyright © 2020 Engqvist, Parris, Kovács, Rönnerman, Sundfeldt, Karlsson and Helou.

Références

Biomed Res Int. 2019 Feb 07;2019:6341967
pubmed: 30881993
Oncol Rep. 2019 Jun;41(6):3189-3200
pubmed: 31002363
Mol Biosyst. 2017 Feb 28;13(3):549-555
pubmed: 28102867
Mol Oncol. 2015 Mar;9(3):569-85
pubmed: 25468710
Biochem Pharmacol. 2019 May;163:46-59
pubmed: 30710516
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nature. 2006 Nov 30;444(7119):629-32
pubmed: 17108971
PLoS One. 2013 Jul 16;8(7):e68667
pubmed: 23874713
Oncogene. 2017 Sep 21;36(38):5356-5368
pubmed: 28534507
PLoS One. 2018 Feb 16;13(2):e0192881
pubmed: 29451900
J Thorac Dis. 2018 Oct;10(10):5714-5726
pubmed: 30505479
Biochem Biophys Res Commun. 2019 May 28;513(2):340-346
pubmed: 30955858
Sci Rep. 2017 Jun 16;7(1):3673
pubmed: 28623285
Virchows Arch. 2012 Mar;460(3):237-49
pubmed: 22322322
BMC Cancer. 2019 Sep 18;19(1):928
pubmed: 31533654
Nat Rev Cancer. 2009 Oct;9(10):749-58
pubmed: 19776744
Comput Biol Chem. 2008 Dec;32(6):462-8
pubmed: 18757239
Clin Sci (Lond). 2019 Oct 30;133(20):2085-2105
pubmed: 31654063
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
Dig Dis Sci. 2019 Oct;64(10):2878-2892
pubmed: 30949905
Oncol Lett. 2019 Apr;17(4):3851-3861
pubmed: 30930987
Cell Death Dis. 2019 Jan 25;10(2):74
pubmed: 30683849
Cell Res. 2010 Jun;20(6):614-21
pubmed: 20404858
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
PLoS One. 2014 Nov 17;9(11):e112275
pubmed: 25401743
Int J Biol Sci. 2018 Apr 5;14(5):531-541
pubmed: 29805304
Cell Biosci. 2019 Sep 18;9:75
pubmed: 31548876
PLoS One. 2014 Apr 28;9(4):e95974
pubmed: 24776823
Mol Cell Proteomics. 2008 Oct;7(10):2019-27
pubmed: 18669619
Int J Gynecol Pathol. 2010 May;29(3):203-11
pubmed: 20407318
Am J Surg Pathol. 2020 Feb;44(2):149-161
pubmed: 31498173
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Gynecol Oncol. 2010 Jan;116(1):50-6
pubmed: 19822358
Cell Cycle. 2019 Jul;18(14):1601-1618
pubmed: 31135262
Cancer Res. 2013 Apr 15;73(8):2529-39
pubmed: 23436799
Med Sci Monit. 2018 Jun 08;24:3863-3872
pubmed: 29880787
J Pathol Clin Res. 2018 Oct;4(4):250-261
pubmed: 30062862
Am J Pathol. 2013 Apr;182(4):1391-9
pubmed: 23499052
Cancer Genet. 2019 Jun;235-236:57-64
pubmed: 31078449
Breast Cancer Res Treat. 2007 Mar;101(3):305-15
pubmed: 16821082
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Gynecol Oncol. 2019 Sep;154(3):516-523
pubmed: 31340883
Haematologica. 2019 Mar;104(3):576-586
pubmed: 30262568
EMBO J. 2005 Oct 19;24(20):3519-31
pubmed: 16193066
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
pubmed: 3893381
Tumour Biol. 2015 Sep;36(9):6901-8
pubmed: 25851347
Nat Commun. 2019 May 14;10(1):2147
pubmed: 31089132
Nature. 2019 Jan;565(7739):372-376
pubmed: 30626964
J Transl Med. 2014 May 20;12:134
pubmed: 24885308
PLoS Med. 2012;9(5):e1001216
pubmed: 22675273

Auteurs

Hanna Engqvist (H)

Department of Oncology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Toshima Z Parris (TZ)

Department of Oncology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Anikó Kovács (A)

Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Elisabeth Werner Rönnerman (EW)

Department of Oncology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Karin Sundfeldt (K)

Department of Obstetrics and Gynecology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Per Karlsson (P)

Department of Oncology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Khalil Helou (K)

Department of Oncology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Classifications MeSH